Risk factor
Negligible price volatility
Profitability factor
Excellent growth
About
Sunway Berhad, established in 1974 and headquartered in Subang Jaya, Malaysia, operates as an investment holding company with a diverse business portfolio spanning Malaysia, Singapore, China, India, Australia, Indonesia, and other international markets. This subsidiary of Sungei Way Corporation Sdn. Bhd. focuses on several core activities. Its Property Development arm is responsible for conceiving and executing residential and commercial real estate projects. Complementing this, the Property Investment division manages, operates, and leases a broad range of assets, including properties, popular theme parks, hotels, and recreational facilities. This segment also engages in travel agency and time-sharing ventures, and makes strategic investments in real estate investment funds. The Construction segment undertakes extensive building and civil engineering initiatives, alongside providing specialized mechanical, electrical, and piling services. In Trading and Manufacturing, the company produces and distributes a variety of construction and industrial products, essential building materials, and commercial vehicles. Meanwhile, its Quarry operations involve extracting raw materials and manufacturing aggregates, asphalt premix, and ready-mixed concrete. Sunway Berhad's Other Businesses segment encompasses a wide array of activities. It manufactures diverse precast concrete products such as vitrified clay pipes, interlocking pavers, and various types of concrete piles. This segment also offers corporate services including secretarial, share registration, and management support, along with financial services like leases and hire purchases. Additional offerings span interior design, loyalty programs, financial technology solutions (online remittance, venture capital fund management, credit rating), and training. Strategic investments in this segment include online media, electronic parcel locker networks, petrol station operations, and the retail of pharmaceutical products.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,
Target Price
The average target price of 5211.KL is 6.1 and suggests 16.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in